Merck to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual ConferenceBusiness Wire • 11/30/20
Merck to pay $425 million upfront to buy COVID-19 treatment developer OncoImmuneMarket Watch • 11/23/20
Merck Submits Applications for Licensure of V114, the Company's Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines AgencyBusiness Wire • 11/23/20